CCM
FDMT icon

CAAS Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

CAAS Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,000
Closed -$217K – 1118
2021
Q1 		$217K Hold
5,000
– – ﹤0.01% 1032
2020
Q4 		$207K Buy
+5,000
New +$206K ﹤0.01% 758

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

CAAS Capital Management's FDMT Position: Q2 2021 in Review

CAAS Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2021, closing a stake of 5,000 shares — an estimated $217K sold.

CAAS Capital Management first reported a position in FDMT in Q4 2020 and held it in 2 quarters. The position peaked at $217K in Q1 2021. 56 funds tracked by Wall St. Rank hold FDMT as of Q2 2021.

  • CAAS Capital Management reported no remaining 4D Molecular Therapeutics position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 5,000 4D Molecular Therapeutics shares in Q2 2021, an estimated $217K.
  • CAAS Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's 4D Molecular Therapeutics position peaked at $217K in Q1 2021.
  • 56 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.